Foresite Capital Management III’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Foresite Capital Management III’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-63,627	Closed	-$919K	–	28
2016 Q4	$919K	Sell	63,627 -391,963	-86%	-$6.89M	0.4%	18
2016 Q3	$10.5M	Sell	455,590 -234,679	-34%	-$4.47M	4.91%	6
2016 Q2	$11.5M	Buy	690,269 +193,269	+39%	+$3.9M	7.86%	5
2016 Q1	$7.88M	Buy	497,000 +37,000	+8%	+$657K	6.1%	4
2015 Q4	$14.9M	Buy	+460,000	New	+$19.9M	13.19%	2

Other funds holding GBT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

WSC

White Square Capital London, United Kingdom $14.7M AUM 151.72% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Foresite Capital Management III's GBT Position: Q1 2017 in Review

Foresite Capital Management III sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2017, closing a stake of 63,627 shares — an estimated $919K sold.

Foresite Capital Management III first reported a position in GBT in Q4 2015 and held it in 5 quarters. The position peaked at $14.9M in Q4 2015. 116 funds tracked by Wall St. Rank hold GBT as of Q1 2017.

Foresite Capital Management III reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
Foresite Capital Management III sold 63,627 Global Blood Therapeutics, Inc. shares in Q1 2017, an estimated $919K.
Foresite Capital Management III first reported a position in Global Blood Therapeutics, Inc. in Q4 2015 and held it in 5 quarters.
Foresite Capital Management III's Global Blood Therapeutics, Inc. position peaked at $14.9M in Q4 2015.
116 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2017.

Based on Foresite Capital Management III's 13F filing for Q1 2017, filed 12 May 2017.